Project Grant R01CA317444
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $628K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Cancer Institute, part of the National Institutes of Health, awarded $508,651 to the University of Wisconsin–Madison on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and exploit therapeutically the role of neuropeptide receptor PAC1 in tumor-infiltrating pericytes during melanoma progression. The research investigates how PACAP-expressing neurons within the melanoma microenvironment interact with PAC1-expressing pericytes to drive disease...
- The National Cancer Institute awarded the University of Wisconsin - Madison $650,369 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop targeted immunostimulatory dual drug conjugates for treating metastatic castration-resistant prostate cancer. The award funds research into radioimmunostimulants that co-deliver two therapeutic payloads with different mechanisms of action. The research addresses a critical clinical gap: approximately 33 percent of...
- The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $988,320 on September 11, 2025, under the Cancer Biology Research program (CFDA 93.396). The award funds research characterizing the involvement of FXR1 (Fragile X Mental Retardation Autosomal Related Protein-1), an RNA binding protein, in ovarian cancer progression. The research focuses on how FXR1 mRNA is encapsulated...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded University of Wisconsin–Madison $634,791 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) for development of shark antibody radiopharmaceuticals (SHARPs) targeting lineage plasticity in castration-resistant prostate cancer. The funded work develops bispecific antibody constructs that engage two antigens simultaneously to overcome treatment...
- The National Cancer Institute awarded Emory University $602,847 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer, particularly in BRCA1-deficient patients. The project examines the role of MAN1C1, a glycosyl hydrolase, in breast cancer progression, immune evasion, and therapeutic resistance. The research addresses a critical gap: approximately 50–70 percent of...
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Cancer Institute awarded the University of Wisconsin - Madison $699,587 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms by which MLL-partial tandem duplication (MLLPTD) drives acute myeloid leukemia and myelodysplastic syndromes. The project leverages targeted mass spectrometry and newly developed antibodies to define how allelic complexity modifies MLLPTD protein interactions, chromatin binding, and gene regulatory...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...